Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tcm-Enriched T Cells
Grade III Lymphomatoid Granulomatosis
Explore 4 assets in Grade III Lymphomatoid Granulomatosis →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01815749CT.gov Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Grade III Lymphomatoid Granulomatosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tcm-Enriched T Cells (this asset) | City of Hope Medical Center | P1 | CC · 43 |
| Fludarabine | Case Comprehensive Cancer Center | P2 | BBB |
| Cyclophosphamide | University of Chicago | P2 | BBB |
| Etoposide | Fred Hutchinson Cancer Center | P2 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BBB |
| Rituximab | Mayo Clinic | P2 | BBB |
| Dexasone | Mayo Clinic | P2 | BBB |
| Romidepsin | Mayo Clinic | P2 | BB |
| Carboplatin | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Grade III Lymphomatoid Granulomatosis cohort
Other indications for Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tcm-Enriched T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Cutaneous B-Cell Lymphoma | — | P1 | CC · 43 |
| Intraocular Lymphoma | — | P1 | CC · 43 |
| Burkitt Lymphoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tcm-Enriched T Cells in Grade III Lymphomatoid Granulomatosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-cd19car-cd28-cd3zeta-egfrt-expressing-tcm-enriched-t-cells-grade-iii-lymphomatoid-granulomatosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →